Egrifta (Tesamorelin) + MOTS-c Stack: Complete Protocol

What Is Tesamorelin (Egrifta) and What Does It Do?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pituitary GH secretion. The FDA approved it in 2010 under the brand name Egrifta specifically for excess visceral abdominal fat in HIV-infected adults with lipodystrophy, then approved the reformulated Egrifta SV in 2019 [1]. Outside that labeled indication it is used off-label for visceral adiposity in metabolic syndrome and age-related GH decline.

Mechanism of Action

Tesamorelin binds GHRH receptors on pituitary somatotrophs and triggers pulsatile GH release. That pulse drives hepatic IGF-1 synthesis, which in turn promotes lipolysis in visceral adipose tissue. Critically, tesamorelin preserves the physiological pulsatility of GH secretion rather than providing a fixed supraphysiological level, a feature that distinguishes it from direct GH injections [2].

Clinical Evidence Base

The Phase III LIPO-010 trial (N=816 HIV-positive adults) showed tesamorelin 2 mg/day reduced visceral adipose tissue by 18% versus 5% with placebo after 26 weeks (P<0.001) [3]. A 52-week extension confirmed the effect was maintained with continued use and reversed within 25 weeks of discontinuation. Triglycerides fell by roughly 50 mg/dL in treated patients. IGF-1 levels rose significantly, requiring routine monitoring.

What Tesamorelin Does Not Do

It does not meaningfully reduce subcutaneous fat, improve lean mass substantially in non-HIV populations, or substitute for lifestyle modification. The FDA label explicitly states it is not indicated for weight loss in the general population [1].

What Is MOTS-c and Why Is It Used?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded in mitochondrial DNA and first characterized by Lee et al. In 2015 [4]. It circulates in human plasma and rises acutely with exercise. Researchers classify it as a mitokine, a signaling molecule released by mitochondria in response to metabolic stress.

Mechanism of Action

MOTS-c activates AMPK (AMP-activated protein kinase) and the FOXO1 transcription pathway, improving insulin sensitivity and glucose uptake in skeletal muscle independent of insulin [4]. In rodent models, systemic MOTS-c administration reversed diet-induced and age-associated insulin resistance. A 2021 study in Cell Metabolism demonstrated that circulating MOTS-c declines with age in humans, and that exogenous MOTS-c extended median lifespan in aged mice by roughly 18% [5].

Human Evidence Gaps

No large randomized human trial of exogenous MOTS-c exists as of early 2025. Two small Phase I safety studies have been completed, and an NIH-funded trial in older adults with obesity (NCT05052164) is ongoing [6]. Current human use is entirely off-label, compounded, and practitioner-supervised. Any clinician presenting MOTS-c as established therapy is overstating the evidence.

Why Practitioners Stack It

MOTS-c's AMPK activation complements tesamorelin's IGF-1 pathway. Where tesamorelin drives GH-mediated lipolysis from the top down (pituitary to adipose), MOTS-c targets skeletal-muscle glucose metabolism from the cellular level up. The combination theoretically addresses visceral fat via two non-overlapping mechanisms. That is the mechanistic case for the stack. The clinical case awaits controlled data.

Rationale for Combining Tesamorelin and MOTS-c

The two peptides act on different receptor systems without known pharmacokinetic interactions. Tesamorelin operates through the GHRH-GH-IGF-1 axis. MOTS-c acts intracellularly through AMPK and the one-carbon cycle. Neither peptide is metabolized by CYP450 enzymes to a clinically significant degree, reducing the probability of traditional drug-drug interactions at the metabolic level [7].

Complementary Metabolic Pathways

| Pathway | Tesamorelin | MOTS-c | |---|---|---| | GH/IGF-1 axis | Directly stimulates | No direct effect | | AMPK activation | Indirect, modest | Primary mechanism | | Visceral lipolysis | Strong evidence | Indirect, via insulin sensitization | | Skeletal muscle glucose uptake | Minimal | Primary target | | Mitochondrial biogenesis | Not established | Preclinical evidence |

Patient Populations Most Likely to Benefit

Practitioners most often consider this stack for adults with:

• HIV-associated lipodystrophy already on Egrifta who show suboptimal metabolic improvement
• Metabolic syndrome with elevated visceral adipose tissue plus insulin resistance (off-label for both)
• Age-related decline in both GH pulsatility and MOTS-c plasma levels, as documented in cross-sectional human data [5]
• Athletes or high-performing adults prioritizing body composition and mitochondrial function

None of these applications outside HIV lipodystrophy carry FDA approval for tesamorelin, and MOTS-c carries no FDA approval for any indication.

Where the Evidence Is Thin

The mechanistic argument for this stack is coherent but inferential. Animal models use intraperitoneal MOTS-c at doses that do not translate directly to human subcutaneous dosing. Practitioner forums report outcomes, but those reports are subject to confounding from diet, training, and concurrent therapies. Patients should understand this distinction before starting.

Complete Dosing Protocol

Tesamorelin (Egrifta) Dosing

The FDA-approved dose is 2 mg subcutaneously once daily, injected into the abdomen, thighs, or upper arms, rotating sites [1]. Off-label use in non-HIV populations sometimes starts at 1 mg/day to assess IGF-1 response before titrating to 2 mg. Injections should be given in the evening, ideally 60 to 90 minutes after the last meal and before sleep, to align with the natural GH pulse that occurs during slow-wave sleep [2].

The prescribing physician must check IGF-1 at baseline. If IGF-1 exceeds the age- and sex-adjusted upper limit of normal, tesamorelin should be dose-reduced or discontinued. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states that IGF-1 should remain within the reference range during any GH-axis therapy [8].

MOTS-c Dosing

No FDA-approved dosing protocol exists. Based on current Phase I safety data and practitioner-reported experience, most compounding-pharmacy prescribers use:

• Dose: 5 mg to 10 mg per injection
• Frequency: 3 to 5 times per week (not daily; some clinicians allow a 2-day rest to avoid receptor desensitization, though that rationale remains theoretical)
• Route: Subcutaneous injection, abdomen or thigh
• Timing: Morning or 30 minutes before exercise to align with the exercise-mimetic properties of MOTS-c

Cycle length in practitioner protocols ranges from 8 to 16 weeks, followed by a 4- to 8-week break. That cycle structure mirrors how MOTS-c was administered in the 2021 aged-mouse study [5], though direct extrapolation carries obvious limitations.

Stack Timing Summary

| Time of Day | Action | |---|---| | Morning (or pre-exercise) | MOTS-c 5 to 10 mg subcutaneous | | Evening (60 to 90 min post-meal) | Tesamorelin 2 mg subcutaneous | | Avoid | Injecting both peptides simultaneously at the same site |

Monitoring and Safety

Routine Labs on Tesamorelin

The FDA label for Egrifta SV specifies IGF-1 monitoring at baseline and periodically during treatment [1]. The HealthRX medical team recommends the following minimum panel for any patient on this stack:

• IGF-1 (baseline, 6 weeks, then every 6 months)
• Fasting glucose and HbA1c (tesamorelin can impair glucose tolerance)
• Fasting lipid panel (visceral fat reduction may alter lipids beneficially, but monitoring confirms direction)
• CMP for hepatic and renal function
• CBC

Tesamorelin Safety Signals

The LIPO-010 trial reported the most common adverse effects as injection-site reactions (12.4% tesamorelin vs. 6.2% placebo), peripheral edema (6.3% vs. 2.5%), and arthralgia (7.1% vs. 3.4%) [3]. Glucose intolerance occurred at a higher rate with tesamorelin, and the FDA label carries a warning about potential fluid retention and worsening insulin resistance in susceptible patients [1].

Tesamorelin is absolutely contraindicated in:

• Active malignancy (endogenous GH may promote tumor growth)
• Pregnancy
• Hypersensitivity to tesamorelin or mannitol
• Disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor, cranial irradiation)

MOTS-c Safety Profile

Human safety data is limited to small early-phase studies. Rodent studies at doses up to 15 mg/kg showed no overt toxicity [4]. The most commonly reported adverse event in practitioner-supervised human use is mild injection-site redness, resolving within 24 hours. No serious adverse events attributable to MOTS-c have been published as of January 2025, but the absence of large-scale trial data means rare events could remain undetected.

Patients with autoimmune conditions should discuss MOTS-c with their physician before use, given that AMPK activation modulates immune-cell metabolism and could theoretically affect disease activity, a mechanism documented in preclinical models of systemic lupus [9].

Drug Interactions

Tesamorelin may reduce the activity of CYP3A4-metabolized drugs (e.g., cyclosporine) because GH axis activity can modestly alter hepatic enzyme expression [7]. Patients on immunosuppressants, anticoagulants, or corticosteroids should have those drugs monitored more closely after starting tesamorelin. MOTS-c has no known clinically significant drug interactions, but human interaction data is essentially nonexistent.

Practical Injection Technique

Both peptides are administered subcutaneously. Standard technique applies:

1. Reconstitute lyophilized MOTS-c with bacteriostatic water per compounding pharmacy instructions. Egrifta SV comes pre-formulated as a 1 mg/mL solution in a multi-dose vial.
2. Use a 27- to 29-gauge, 0.5-inch needle for both.
3. Pinch skin, insert at 45 degrees in leaner patients or 90 degrees with adequate subcutaneous tissue, inject slowly.
4. Rotate sites systematically. Repeated injection at the same site causes lipohypertrophy that impairs absorption.
5. Store Egrifta SV refrigerated (2°C to 8°C). Reconstituted MOTS-c should be used within 14 days if refrigerated.

Setting Realistic Expectations

Tesamorelin's visceral fat reduction in HIV lipodystrophy trials averaged 18% over 26 weeks [3]. In metabolic-syndrome populations studied off-label, reductions of 10 to 15% in visceral adipose tissue have been reported in smaller observational series. These numbers require sustained daily injections; the effect reverses after stopping [3].

MOTS-c's contribution to the stack in humans is currently unmeasured. Rodent data suggests it may amplify insulin sensitivity and mitochondrial efficiency within 4 to 8 weeks of administration [4], but whether that translates to additive fat loss or muscle-function improvement in people on tesamorelin is unknown.

The Endocrine Society notes that "the use of GH secretagogues or GH-releasing factors in non-GH-deficient individuals for anti-aging or body-composition purposes lacks a sufficient evidence base to make clinical recommendations" [8]. That assessment covers tesamorelin's off-label use squarely, and extends to any stack built around it.

Patients who combine this stack with a 300 to 500 kcal daily deficit and 150 minutes per week of aerobic exercise (per American Heart Association guidelines [10]) are far more likely to see meaningful visceral fat reduction than those relying on peptides alone. The peptides may amplify a favorable metabolic environment; they do not create one independently.

Who Should Not Use This Stack

The following patient groups should avoid or defer this stack pending specialist evaluation:

• Anyone with a personal or family history of pituitary adenoma or active cancer
• Pregnant or breastfeeding individuals
• Patients with uncontrolled type 2 diabetes (HbA1c above 9%), given tesamorelin's glucose-tolerance effects
• Patients with carpal tunnel syndrome (fluid retention from GH axis stimulation worsens this condition)
• Individuals under age 18, where GH-axis manipulation carries growth-plate risks
• Patients with severe hepatic impairment (tesamorelin's metabolic handling may be altered)

Sourcing and Legal Considerations

Egrifta SV (tesamorelin 1 mg/mL) requires a prescription. It is manufactured by Theratechnologies and is commercially available at US pharmacies, though prior authorization is often required and off-label coverage is inconsistent. Cash-pay costs run approximately $1,200, $1,800 per month without insurance.

MOTS-c is not approved by the FDA for any use. It is available only through compounding pharmacies operating under 503A or 503B regulations. The FDA's guidance on compounded peptides has evolved rapidly; in 2024, the FDA finalized a list of bulk drug substances that may be used in compounding, and MOTS-c's status should be verified with the prescribing physician and compounding pharmacy at the time of prescription. Purchasing MOTS-c from unregulated online sources carries risks of underdosing, contamination, and legal liability.